 |
| |||
| cardiac myosin inhibitors (Two cardiac myosin inhibitors – mavacamten and aficamten – have been developed that modify myosin mechanochemistry and reduce sarcomere force generation, myocardial hypercontractility and left ventricular outflow tract obstruction in a dose-dependent fashion.: мавакамтен, афикамтен Nidarat) | |||